Matches in Wikidata for { <http://www.wikidata.org/entity/Q63812156> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- Q63812156 description "clinical trial" @default.
- Q63812156 description "ensayu clínicu" @default.
- Q63812156 description "klinisch onderzoek" @default.
- Q63812156 description "клінічне випробування" @default.
- Q63812156 name "A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large" @default.
- Q63812156 type Item @default.
- Q63812156 label "A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large" @default.
- Q63812156 prefLabel "A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large" @default.
- Q63812156 P1050 Q63812156-53DAB303-60EC-4923-90C3-CC6BF653A46C @default.
- Q63812156 P1132 Q63812156-E2DC0861-E598-4879-B0C1-62374028F98A @default.
- Q63812156 P1476 Q63812156-44781BD6-1697-4749-98A9-ECB284FE1762 @default.
- Q63812156 P17 Q63812156-04B1E2D2-C403-46C4-A704-08ACF81FDB34 @default.
- Q63812156 P17 Q63812156-2817C886-A790-4CCB-AF19-12C429351548 @default.
- Q63812156 P17 Q63812156-A2486A08-1DEA-4B53-A581-C9473618262C @default.
- Q63812156 P17 Q63812156-BBA31CA4-A040-4EF2-9520-56E41B969C65 @default.
- Q63812156 P2899 Q63812156-B91D1E13-D009-4825-9CF6-98B96DCFD1E3 @default.
- Q63812156 P3098 Q63812156-F6D8D9D9-C090-48C6-954E-44AE48DEA8A8 @default.
- Q63812156 P31 Q63812156-AB88E611-32AE-4081-8308-1A57549D9676 @default.
- Q63812156 P4844 Q63812156-535DD329-DC7F-4877-BB51-49DA7AD7D93E @default.
- Q63812156 P4844 Q63812156-BF39BCA4-2C67-4B15-A576-387C1B6D111D @default.
- Q63812156 P4844 Q63812156-BF3A7392-1B1F-4150-B951-8E5CD13F938B @default.
- Q63812156 P580 Q63812156-7A6B5215-C36A-40AA-A66D-36A590F04F95 @default.
- Q63812156 P582 Q63812156-20ADE046-1BA2-4D58-A716-76E5FDF75458 @default.
- Q63812156 P6099 Q63812156-D95BB6BE-8545-4367-8D4F-3D6FDD938447 @default.
- Q63812156 P6099 Q63812156-F7AA4D4C-07A1-4AD8-8629-69BA798A64DE @default.
- Q63812156 P6153 Q63812156-17DE6A0F-9467-41BA-8FAA-82E100E377D4 @default.
- Q63812156 P6153 Q63812156-42EE3672-B939-4369-8ED1-3EAAA8260AB8 @default.
- Q63812156 P6153 Q63812156-6D9772BB-79D0-40D3-8E50-C190EE5A788C @default.
- Q63812156 P6153 Q63812156-70B4E004-F1D5-4B83-8FB6-89D3F4FD4595 @default.
- Q63812156 P6153 Q63812156-89ACDE51-E8FF-4D16-883C-6041F051F684 @default.
- Q63812156 P6153 Q63812156-96EE410C-0A02-4F5C-98D0-A058A961CD60 @default.
- Q63812156 P6153 Q63812156-A8CEADD9-7C97-4987-A1D8-FAC65B6A9524 @default.
- Q63812156 P6153 Q63812156-AE16079C-4496-4735-90CE-A0E0FBFC381E @default.
- Q63812156 P6153 Q63812156-AE1892C5-7A10-4D49-BF6D-1331B14191BF @default.
- Q63812156 P6153 Q63812156-B01362D8-3BFF-4418-BD51-C0B9DDB10F6E @default.
- Q63812156 P6153 Q63812156-C733BF7D-EE80-4B77-8929-53DFA7C9A131 @default.
- Q63812156 P6153 Q63812156-E41ECDEA-4DAF-4B67-8935-2A9B9EB11C77 @default.
- Q63812156 P8363 Q63812156-5D135D54-363F-473C-BEA6-0D16D13580E8 @default.
- Q63812156 P859 Q63812156-446C6A2B-EAD4-43C1-B546-2E963D6A5CBE @default.
- Q63812156 P1050 Q208414 @default.
- Q63812156 P1132 "+140" @default.
- Q63812156 P1476 "A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Patients With Relapsed or Refractory Follicular Lymphoma and Obinutuzumab or Rituximab in Combination With Idasanutlin and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma" @default.
- Q63812156 P17 Q183 @default.
- Q63812156 P17 Q30 @default.
- Q63812156 P17 Q408 @default.
- Q63812156 P17 Q664 @default.
- Q63812156 P2899 "+18" @default.
- Q63812156 P3098 "NCT03135262" @default.
- Q63812156 P31 Q30612 @default.
- Q63812156 P4844 Q23671272 @default.
- Q63812156 P4844 Q389496 @default.
- Q63812156 P4844 Q412323 @default.
- Q63812156 P580 "2017-06-15T00:00:00Z" @default.
- Q63812156 P582 "2022-10-27T00:00:00Z" @default.
- Q63812156 P6099 Q42824440 @default.
- Q63812156 P6099 Q5452194 @default.
- Q63812156 P6153 Q1278898 @default.
- Q63812156 P6153 Q131252 @default.
- Q63812156 P6153 Q1468161 @default.
- Q63812156 P6153 Q1774589 @default.
- Q63812156 P6153 Q30282606 @default.
- Q63812156 P6153 Q39988 @default.
- Q63812156 P6153 Q4731305 @default.
- Q63812156 P6153 Q4803501 @default.
- Q63812156 P6153 Q492467 @default.
- Q63812156 P6153 Q50036845 @default.
- Q63812156 P6153 Q624119 @default.
- Q63812156 P6153 Q7989074 @default.
- Q63812156 P8363 Q78089383 @default.
- Q63812156 P859 Q212646 @default.